AB Science expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027
AB Science SA said it expects to resume AB8939 Phase 1 in Q1 2027 and masitinib Phase 3 in Q4 2027, revising its operating plan after a GCP inspection by France, Denmark and Greece authorities.